221 results about "Addiction" patented technology

The invention discloses an artificial intelligence early warning intervention system for short video addiction of children, and relates to the technical field of crossing of artificial intelligence and mental health. The system comprises a data collection and preprocessing module, an addiction risk assessment model module, a personalized intervention suggestion module, an intelligent early warning and feedback module and a parent education and support module. The short video use behavior of the child is monitored in real time, the addiction risk of the child is accurately evaluated, once it is detected that the child has the addiction risk, the system can automatically send early warning information to a guardian and provide personalized intervention suggestions, and the timely and effective early warning and intervention mechanism helps the guardian to take measures in time, so that the risk of addiction of the child is effectively evaluated. Children are guided to reasonably use short videos and are prevented from being addicted in the short videos, so that physical and psychological health and normal learning life of the children are protected.

Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of using them for treating and preventing addictions and overdoses.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

The present invention relates to a heterocyclic carbonyl derivative modulator, a preparation method therefor, and the use thereof. Specifically, the present invention relates to a compound represented by general formula (II-B), a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof as a modulator in the treatment of Alzheimer's disease, schizophrenia, pain, addiction, and sleep disorders, wherein each substituent in general formula (II-B) is as defined in the description.

Provided is a polypeptide which contains a polypeptide having at least 80%, 85%, 90%, 95%, or 99% identity to amino acid sequence MTYRPGYNPFG (SEQ ID NO: 41) or amino acid sequence AKGYYRPYGVPV (SEQ ID NO: 22), or a polypeptide having one or more amino acid substitutions, deletions and / or additions relative to the amino acid sequence as shown in SEQ ID NO: 41 or 22. The provided polypeptide can interfere with the binding of a Brag2 synaptic protein to the C terminus of an AMPA receptor, thereby inhibiting NMDA-mediated excessive endocytosis of an AMPA receptor and neuronal apoptosis, and playing a role in protecting neuronal cell activity. Therefore, the polypeptide has application prospects and potential development values as a drug for treating nervous system diseases such as strokes, depression, Alzheimer's disease and drug addiction.

A system and method adapted to introduce vibrational waves into a body of a subject includes first and second vibration contacts and first and second vibration sources. The system and method are useful for the relief and symptoms of distress including pain and anxiety and more specifically to addiction withdrawal.

The invention discloses an addiction-related epitope intelligent prediction and antibody optimization design method, and belongs to the field of medicine.The design method specifically comprises the following steps that firstly, multi-source heterogeneous biological information data are integrated, and the potential space structure, dynamic stability and regulation and control characteristics of an epitope are extracted; iI, identifying a low-immunogenicity region in the addiction target, and generating a high-adaptability candidate epitope according to the identified low-immunogenicity region; iII, optimizing antibody design according to the high-adaptability candidate epitopes, and dynamically adjusting the antibody design according to real-time molecular dynamics simulation feedback; according to the method, double optimization of antibody affinity and safety can be realized, the design efficiency and accuracy are improved, the problems of blind screening and low-efficiency verification in a traditional method are avoided, and the recognition redundancy of the antibody is improved, so that the effective period of a drug is prolonged, and the off-target risk is reduced.

The invention provides a user generated content anti-addiction method and system, and belongs to the technical field of data analysis, and the method comprises the steps: building a first label of current page content at the current time t, and a plurality of second labels corresponding to a plurality of historical page contents in a time period T before the current time t; comparing the first label with the plurality of second labels one by one, and if the similarity or distance value of the first label and the second label is greater than a preset threshold value, judging that the user enters an addiction state; if the user enters the addiction state, an alarm signal is sent out. According to the method, personalized intervention can be performed according to actual conditions such as interests, preferences and behavior modes of different users, so that anti-addiction measures are more accurate and effective, the safety of generating a content platform by the user is improved, and the user experience is improved.

The invention relates to a heterocyclic carbonyl derivative regulator as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and a use thereof as a modulator in the treatment of Alzheimer's disease, schizophrenia, pain, addiction and sleep disorders, each substituent in the general formula (I) being as defined in the specification. # imgabs0 #

Embodiments include methods of determining a patient's susceptibility (i.e., risk) of becoming dependent and / or addicted to an addictive substance. The addictive substance can be an opioid receptor agonist. In aspects, the methods include use of a lateral flow assay (LFA) test with up converting phosphors (UCPs). If a patient is deemed susceptible to addiction, a monitoring / dispensing system can be used to administer the addictive substance (e.g., opioid receptor agonist).

Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.

Disclosed in the present invention are a drug for treating or preventing methamphetamine addiction, and the use. Also disclosed is a new use of an ERK inhibitor. In the present invention, the use of an ERK inhibitor in drug addiction is studied. The inhibitory effect of GDC-0994 in the treatment of methamphetamine addiction is studied by means of methamphetamine addiction models (including a place preference model and a self-administration experiment model), and it is found that the administration of the ERK inhibitor GDC-0994 can significantly reduce the seeking and ingesting of methamphetamine in animals, that is, the ERK inhibitor GDC-0994 can antagonize methamphetamine addiction, this indicates that the inhibition of ERK by GDC-0994 can effectively treat methamphetamine addiction.

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

The invention relates to a game anti-addiction processing method and device, a server, a computer readable storage medium and a computer program product, and the method comprises the steps: for a level x, the level x has a preset difficulty Ax; after the user passes through the checkpoint x, the average clearance difficulty Mx of all checkpoints passed by the user is calculated, and the clearance difficulty value of each checkpoint is in direct proportion to the round number; comparing the preset difficulty Ax with the customs clearance difficulty Mx; when the preset difficulty Ax is larger than the customs clearance difficulty Mx, the difference value ax-P of the probability of the optimal condition of the current level and the difficulty coefficient P is used as the probability of a new optimal condition, and the sum value cx + P of the probability of the worst condition of the current level and the difficulty coefficient P is used as the probability of a new worst condition; when the customs clearance difficulty Ax is smaller than the customs clearance difficulty Mx, the probability of the optimal condition and the probability of the worst condition of the current checkpoint are adjusted. The level difficulty can be dynamically adjusted, and the user is prevented from being addicted to the game for a long time.

Technologies are provided for predicting an individual's likelihood of addiction or relapse to pharmaceuticals that include controlled or addictive substances. The prediction can be used to generate an alert that, in some aspects, prevents care provider actions in an electronic health record system that are related to the addictive pharmaceutical until the prediction is acknowledged. Further, the data used as input in the predictive modeling can be disassociated from the prediction after the prediction is generated.

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and / or solvate thereof. The invention also relates to the use of the compounds of formula (I) as a medicament, in particular for the prevention or treatment of obsessive-compulsive disorder and related behaviors, including addiction, obsessive-compulsive disorder and dietary disorder, and neurodegenerative diseases, such as Parkinson's disease or Alzheimer's disease.

The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disorders, among others CNS disorders.

Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and / or anxiety disorder, each individually or concurrent.

Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided. Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction.

The present invention relates to a compound, of the formula:Wherein variables are as defined in the specification and pharmaceutical composition comprising thereof, more specifically compound of the present invention is thiophenyl and pyrrolyl azepine compound; The compound is serotonin receptor (5-HT2c) ligand, useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).

The invention provides a juvenile network addiction early warning and reminding method and system based on physiological parameters, and belongs to the field of network addiction early warning, and the method comprises the steps: obtaining a facial image, a facial video stream and audio data of a user, and extracting the physiological feature data of the user from the facial image, the facial video stream and the audio data; sending the physiological feature data of the user to a background server; the background server is used for calculating physiological parameters based on the physiological feature data of the user, determining psychological parameters based on the questionnaire text data, the network application use data and the physiological parameters of the user, and calculating an addiction risk score based on the physiological parameters and the psychological parameters; in response to the received addiction risk score of the background server, if the addiction risk score is not less than a preset addiction risk threshold, determining a target early warning level based on the addiction risk score; and generating early warning information based on the target early warning level. According to the application, the addiction state of the juveniles can be accurately monitored and early warned.

A compound having a structure of formula (I), (II), (III), (IV), (V), (VI), or a pharmaceutically acceptable salt, a tautomer, or a solvate thereof for use in treating opioid addiction, withdrawal and / or dependence and / or loss of opioid induced analgesia and / or occurrence of opioid induced hyperalgesia in a subject in need thereof.

The present invention provides a composition for use as anti-addiction in mitragynine addiction symptoms, characterized in that the composition comprises FPL 64176 as an active ingredient by reducing levels of calretinin and dopamine in a subject's brain.

The invention belongs to the field of network addiction detection, and provides a network space addiction behavior index system construction method and device, equipment and a medium, and the method comprises the steps: obtaining an index and an addiction level of a network space addiction behavior, and determining a visual angle; performing two-point anchor point selection processing on the visual angle to obtain an anchor point set; according to the anchor point set, a similarity graph, a diversity graph and a consistency graph of the anchor points are constructed, and the similarity graph, the diversity graph and the consistency graph are used for representing the incidence relation of the view angles; performing fusion calculation on the diversity graph and the consistency graph of the anchor points to obtain a weighted similarity matrix; carrying out eigendecomposition on the weighted similarity matrix to obtain low-dimensional embedded representation, and carrying out supervised training on the low-dimensional embedded representation through a loss function to obtain a network space addiction behavior index system; and network addiction detection is carried out through the network space addiction behavior index system. According to the invention, the accuracy of user network addiction level identification is improved.

The invention relates to a compound as shown in a general formula (A) and a pharmaceutical composition of the compound, and the compound as shown in the general formula (A) can be used for preventing and / or treating diseases related to a central nervous system, such as pain, drug addiction and depression. The invention also relates to preparation and application of the compound. # imgabs0 #

The invention discloses an addiction prevention method suitable for juveniles, which solves the problem that the juveniles are easy to addict when using a mobile intelligent terminal to a certain extent by changing the mode of a graphic decoding module, or a graphic display module, or an audio decoding module or an audio display module of a hardware part of the mobile intelligent terminal.

This invention provides a class of multi-target heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF. These heteropeptides use the small-molecule N-4-piperidinyl-N-phenylpropionamide and the polypeptide-structured neuropeptide FF as chemical templates. A series of peptide-small-molecule hybrid peptides are obtained by chemically coupling the pharmacophores of the N-4-piperidinyl-N-phenylpropionamide analog and the neuropeptide FF. In vivo pharmacological activity identification in animals shows that these heteropeptides possess analgesic activity without opioid-like side effects such as addiction and respiratory depression. Furthermore, compounds 1-4 and compounds 7-9 do not exhibit analgesic tolerance and can be used for long-term analgesic treatment of chronic pain. Therefore, these heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF can be used to prepare analgesic drugs.